DelveInsight reports that several key companies are actively engaged in the ongoing development of treatment therapies for Influenza A.
Influenza A Overview:
The flu vaccine plays a critical role in protecting against seasonal influenza, a disease caused by constantly evolving influenza viruses. Updated every year to target the most prevalent strains—typically covering both influenza A and B—the vaccine helps the immune system build antibodies to fight the virus, reducing illness severity and the risk of serious complications like pneumonia, hospitalization, and death. It is offered in different forms, including inactivated flu shots and live attenuated nasal sprays, to suit various age groups and medical needs.
Widespread immunization is essential for safeguarding public health, especially among high-risk groups such as young children, the elderly, pregnant women, and people with chronic conditions like asthma or cardiovascular disease. By cutting down on flu-related hospital visits and admissions, the vaccine also alleviates pressure on healthcare systems. While the vaccine's effectiveness can vary each season, studies consistently show it significantly reduces the likelihood of severe flu cases. Health authorities such as the CDC and WHO strongly recommend annual flu vaccination as the most effective means of preventing flu outbreaks and promoting community well-being.
Request for a detailed insights report on Influenza A pipeline insights
"Influenza A Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Influenza A Therapeutics Market.
Key Takeaways from the Influenza A Pipeline Report
-
DelveInsight’s Influenza A pipeline report highlights a dynamic and evolving landscape, with multiple companies actively developing new therapies to treat Influenza A. Leading players such as Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, and others are working on innovative drug candidates to enhance the treatment options for this viral infection.
-
Several promising therapies are progressing through various stages of development, including VIR-2482, SAB-176, CD388, FLUZONE QUADRIVALENT, RAPIVAB (peramivir injection), XOFLUZA (baloxavir marboxil), among others.
-
In a notable development, the FDA approved FluMist in September 2025 for self- or caregiver-administration. This nasal spray vaccine, designed to protect against both influenza A and B strains, is now available for individuals aged 2 to 49, improving accessibility and ease of use.
-
Meanwhile, pharmaceutical companies are making significant strides in mRNA vaccine technology for influenza. Moderna’s mRNA-1010 has achieved all primary immunogenicity endpoints in Phase 3 trials, with regulatory filing anticipated in 2025. Pfizer and BioNTech are also advancing their quadrivalent mRNA influenza vaccine, which has shown strong immune responses in early-phase studies.
Influenza A Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Influenza A Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Influenza A treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Influenza A market.
Download our free sample page report on Influenza A pipeline insights
Influenza A Marketed Drugs
-
XOFLUZA (baloxavir marboxil): Genentech/Roche
-
RAPIVAB (peramivir injection): BioCryst Pharmaceuticals
-
FLUZONE QUADRIVALENT: Sanofi
Influenza A Emerging Drugs
-
CD388: Cidara Therapeutics
-
SAB-176: SAb Biotherapeutics
-
VIR-2482: Vir Biotechnology
Influenza A Companies
Multiple leading companies, including Cidara Therapeutics, SAb Biotherapeutics, FluGen, Moderna, Vir Biotechnology, Vaxart, and others, are actively working on developing therapies for Influenza A. Among these, Arcutis Biotherapeutics Inc. has a drug candidate that has progressed the furthest, currently undergoing Phase II clinical trials.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Influenza A pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Influenza A Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Influenza A Therapies and Key Companies: Influenza A Clinical Trials and advancements
Influenza A Pipeline Therapeutic Assessment
• Influenza A Assessment by Product Type
• Influenza A By Stage
• Influenza A Assessment by Route of Administration
• Influenza A Assessment by Molecule Type
Download Influenza A Sample report to know in detail about the Influenza A treatment market @ Influenza A Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Influenza A Current Treatment Patterns
4. Influenza A - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Influenza A Late-Stage Products (Phase-III)
7. Influenza A Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Influenza A Discontinued Products
13. Influenza A Product Profiles
14. Influenza A Key Companies
15. Influenza A Key Products
16. Dormant and Discontinued Products
17. Influenza A Unmet Needs
18. Influenza A Future Perspectives
19. Influenza A Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Influenza A Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
